Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
LeMaitre Vascular, Inc.
LMAT
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $2.3B
$101.63
▲ +2.93%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$79.01 - $118.01
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 17.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized focus on niche vascular intervention market with limited direct competition
- Comprehensive product portfolio addressing multiple steps in vascular procedures
- Established relationships with vascular surgeons and interventional radiologists worldwide
- Proprietary technology in carotid shunts and specialized catheter designs
Bear Case
2 risks
- Low volatility (beta 0.5).
- Significant premium - growth priced in
Growth
Stable outlook
Rising prevalence of peripheral vascular disease due to aging population and diabetes epidemic
Value
Significant premium - growth priced in
Momentum
Weak
-9.0% over 3m
Quality
Excellent
Excellent business quality
Dividend
Modest
0.91% yield
Smart-money signal
Who's buying LMAT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
MAY 5, 2026
Reported EPS of $0.68 vs $0.66 consensus (+3.0% surprise). Revenue of $66.6M vs $66.7M expected (-0.2%).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+3.0%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+14%
+12%
+15%
+11%
+16%
+11%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$55.8M
$54.8M
$55.7M
$59.9M
$64.2M
$61.0M
$64.5M
$66.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
23.6%
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
$127.50
▲ +25.5% vs $101.63
Latest: Barrington · $120.00 · May 6, 2026
2 analysts covering